Table 3.
Analyses of the CAMERA2 Trial Using a Desirability of Outcome Ranking Approach
| Analysis | Chance of a Patient in the Combination Arm Having a Worse Outcome, % (95% CI) | P Valuea | Generalized Odds Ratio (95% CI) | P Valuea |
|---|---|---|---|---|
| Primary analysis | 54.5 (48.9–60.1) | .11 | 1.20 (.95–1.50) | .12 |
| Secondary analyses | ||||
| DOOR-LOSb | 55.6 (49.4–61.6) | 1.25 (.97–1.61) | ||
| DOOR-RADAR | 55.3 (49.2–61.3) | 1.24 (.96–1.58) | ||
| Sensitivity analyses | ||||
| Excluding dialysis patients | 55.6 (49.4–61.6) | 1.25 (.98–1.61) | ||
| AKI defined as 2-fold increase in creatinine | 53 (47.5–58.5) | 1.13 (.90–1.41) | ||
| Only AE reported by the trial's investigators | 52.3 (46.8–57.8) | 1.10 (.88–1.37) | ||
| Missing data analyses | ||||
| Assuming the worst alive category | 54.5 (48.9–60) | 1.20 (.95–1.49) | ||
| Assuming worst outcome for combination therapy and best outcome for standard therapy | 55.4 (49.8–60.9) | 1.24 (.99–1.56) | ||
| Assuming best outcome for combination therapy and worst outcome for standard therapy | 53.6 (48–59.1) | 1.15 (.92–1.44) | ||
Abbreviations: AE, adverse event; AKI, acute kidney injury; CAMERA2, Combination Antibiotics for MEthicillin Resistant Staphylococcus aureus; CI, confidence interval; DOOR, desirability of outcome ranking; LOS, length of stay; RADAR, response adjusted for duration of antibiotic risk.
a P values were not calculated for secondary, sensitivity, and missing data analyses as these are exploratory analyses.
bAnalysis of the DOOR-LOS endpoint included 144 and 132 surviving participants from the standard therapy and combination therapy arms, respectively, for whom LOS data were available. One participant from the standard therapy arm and 2 participants from the combination therapy arm had missing LOS data and were excluded from this analysis.